Francisco Cervantes
#138,861
Most Influential Person Now
Researcher
Francisco Cervantes's AcademicInfluence.com Rankings
Francisco Cervantescomputer-science Degrees
Computer Science
#6545
World Rank
#6900
Historical Rank
Machine Learning
#2164
World Rank
#2192
Historical Rank
Artificial Intelligence
#2426
World Rank
#2467
Historical Rank
Database
#3625
World Rank
#3776
Historical Rank
Download Badge
Computer Science
Francisco Cervantes's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Francisco Cervantes Influential?
(Suggest an Edit or Addition)Francisco Cervantes's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. (2003) (3476)
- Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. (2006) (3337)
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013) (1736)
- JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. (2012) (1499)
- Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (2006) (1300)
- Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (2009) (1255)
- Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders (2010) (1114)
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. (2008) (1098)
- Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. (2007) (893)
- DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. (2011) (833)
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). (2010) (798)
- Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (2017) (754)
- Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. (2007) (747)
- Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. (2011) (745)
- Prognostic discrimination in "good-risk" chronic granulocytic leukemia (1984) (664)
- Mutations and prognosis in primary myelofibrosis (2013) (659)
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (2020) (623)
- Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (2007) (608)
- The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. (2013) (548)
- Prognostic discrimination in "good-risk" chronic granulocytic leukemia. (1984) (504)
- Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment (2008) (456)
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. (2013) (381)
- Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib (2008) (363)
- The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. (2008) (354)
- Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. (2014) (345)
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet (2018) (342)
- Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. (2012) (328)
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. (2015) (310)
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis (2016) (308)
- International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). (2006) (302)
- Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). (2007) (297)
- Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. (1999) (287)
- Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. (2006) (272)
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. (2013) (269)
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients (2014) (269)
- EZH2 mutational status predicts poor survival in myelofibrosis. (2011) (247)
- Outcome of transplantation for myelofibrosis. (2010) (246)
- Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia (2005) (215)
- Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia (2016) (215)
- Thrombosis in primary myelofibrosis: incidence and risk factors. (2009) (213)
- Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group (2015) (211)
- TIPS is a useful long‐term derivative therapy for patients with Budd‐Chiari syndrome uncontrolled by medical therapy (2002) (207)
- A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis (2017) (205)
- Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients (1999) (205)
- Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. (2010) (205)
- Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. (2013) (200)
- Pomalidomide is active in the treatment of anemia associated with myelofibrosis. (2009) (198)
- Myelofibrosis with myeloid metaplasia in young indidviduals: disease characteristics, prognostic factors and identification of risk groups (1998) (193)
- Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. (2012) (193)
- Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders (2008) (192)
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis (2015) (185)
- Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. (1991) (177)
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. (2017) (171)
- Identification of ‘short‐lived’ and ‘long‐lived’ patients at presentation of idiopathic myelofibrosis (1997) (171)
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses (2017) (168)
- Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients (2002) (161)
- How I treat myelofibrosis. (2014) (157)
- Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. (2010) (157)
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. (2018) (155)
- Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance (1992) (151)
- An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. (2015) (147)
- Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature (2004) (141)
- Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. (2015) (139)
- Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients (2010) (135)
- Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. (2008) (131)
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations (2011) (127)
- Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. (1988) (125)
- Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden (2009) (124)
- Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. (1985) (122)
- Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients (2007) (121)
- Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both (2016) (121)
- Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status (2001) (120)
- Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long‐term results in 30 patients (2005) (119)
- Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation (2016) (110)
- Improving survival trends in primary myelofibrosis: an international study. (2012) (106)
- A multivariate analysis of prognostic factors in chronic myeloid leukemia. (1982) (105)
- A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group (2007) (104)
- Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) (100)
- Budd-Chiari Syndrome Secondary to Antiphospholipid Syndrome: Clinical and Immunologic Characteristics of 43 Patients (2001) (96)
- Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. (2003) (95)
- Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. (2014) (94)
- Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up (2014) (94)
- Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis (2017) (94)
- Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. (2014) (88)
- Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia (2012) (87)
- Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. (1996) (84)
- Does ruxolitinib prolong the survival of patients with myelofibrosis? (2017) (83)
- Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia. (2008) (82)
- Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. (2009) (81)
- Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). (2005) (80)
- Liver disease in brucellosis. A clinical and pathological study of 40 cases (1982) (78)
- Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) (2008) (77)
- Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. (2004) (76)
- Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. (2014) (76)
- Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy (2013) (72)
- What are RBC-transfusion-dependence and -independence? (2011) (72)
- Danazol treatment of idiopathic myelofibrosis with severe anemia. (2000) (72)
- Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients (2016) (71)
- Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. (2015) (68)
- Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Chronic Myeloid Leukemia (2003) (67)
- Darbepoetin‐alpha for the anaemia of myelofibrosis with myeloid metaplasia (2006) (67)
- Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. (2012) (67)
- Transfusion‐dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is independent of IPSS or karyotype (2009) (67)
- JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis (2007) (66)
- Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. (1999) (64)
- Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea (2014) (64)
- New and Old Treatment Modalities in Primary Myelofibrosis (2007) (63)
- High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists (2016) (63)
- Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients (1994) (62)
- Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution (2006) (61)
- Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project (2014) (61)
- Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect (2000) (61)
- Epigenetic regulation of PRAME gene in chronic myeloid leukemia. (2007) (60)
- The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. (2004) (59)
- Multiple deletions of mtDNA in two brothers with sideroblastic anemia and mitochondrial myopathy and in their asymptomatic mother. (1994) (59)
- Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF) (2012) (58)
- Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group (2010) (56)
- Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. (2007) (56)
- A study of prognostic factors in blast crisis of Philadelphia chromosome‐positive chronic myelogenous leukaemia (1990) (54)
- Modern management of myelofibrosis (2005) (52)
- Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results (2015) (51)
- Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. (2016) (51)
- ‘Lymphoid’ blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features (1998) (51)
- A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group (2007) (51)
- Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. (2011) (49)
- Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis (2008) (48)
- Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. (2003) (48)
- The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades (1998) (48)
- Deoxycoformycin in the treatment of patients with hairy cell leukemia (2000) (47)
- Management of essential thrombocythemia. (2011) (47)
- Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia (2000) (46)
- Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. (1991) (46)
- A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria (1987) (45)
- Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. (2002) (45)
- Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. (2009) (45)
- Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis (1990) (44)
- Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia (2015) (44)
- Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies (2014) (44)
- A new prognostic system for multiple myeloma based on easily available parameters (1989) (43)
- Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group (2016) (43)
- Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) (2014) (43)
- Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. (2017) (42)
- Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily (2014) (41)
- Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations (2017) (40)
- Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features? (1996) (40)
- [Extramedullary blast crisis in chronic myeloid leukemia]. (1989) (39)
- Blood cell activation in myeloproliferative neoplasms (2009) (39)
- Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases (2019) (38)
- Cerebral vein thrombosis in patients with Philadelphia‐negative myeloproliferative neoplasms An European Leukemia Net study (2014) (38)
- Liver involvement at diagnosis of primary myelofibrosis: A clinicopathological study of twenty‐two cases (1988) (37)
- Hodgkin's disease presenting as a cholestatic febrile illness: incidence and main characteristics in a series of 421 patients (1996) (37)
- Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results (2017) (37)
- Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis (2015) (37)
- Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients (2018) (36)
- Bone marrow histopathology in primary myelofibrosis: Clinical and haematologic correlations and prognostic evaluation (1990) (36)
- Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients (2017) (36)
- Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies. (2002) (36)
- Leukemia risk models in primary myelofibrosis: an International Working Group study (2012) (36)
- Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. (2003) (35)
- Successful treatment by selective arterial embolization of severe retroperitoneal hemorrhage secondary to bone marrow biopsy in post-polycythemic myelofibrosis (2003) (35)
- Portal Hypertension Secondary to Myelofibrosis: A Study of Three Cases (2005) (34)
- A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. (2012) (34)
- Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options. (2006) (34)
- Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia. (1995) (34)
- The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia (2020) (33)
- No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib (2017) (33)
- Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma. (1995) (32)
- The value of detecting surface and cytoplasmic antigens in acute myeloid leukaemia (1992) (32)
- Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study (2020) (32)
- Prognostic Discrimination in "GoodRisk" Chronic Granulocytic Leukemia (2017) (32)
- Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel. (2017) (31)
- Chronic neutrophilic leukaemia preceding for seven years the development of multiple myeloma. (1990) (31)
- Simultaneous occurrence of B-cell chronic lymphocytic leukemia and chronic myeloid leukemia with further evolution to lymphoid blast crisis. (1997) (30)
- Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis (2000) (30)
- IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis (2011) (30)
- Neutrophilic pustulosis associated with chronic myeloid leukemia: a special form of Sweet's syndrome. Report of two cases. (1992) (30)
- Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF) (2013) (29)
- Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence (2013) (28)
- Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT) (2012) (28)
- Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF). (2011) (28)
- Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival (2001) (28)
- Long‐term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group (1994) (28)
- Survivin expression in the progression of chronic myeloid leukemia: A sequential study in 16 patients (2005) (27)
- Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms. (2014) (27)
- How I treat splenomegaly in myelofibrosis (2011) (27)
- Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide, and prednimustine. (1986) (27)
- Bone marrow lymphoid nodules in myeloproliferative disorders: association with the nonmyelosclerotic phases of idiopathic myelofibrosis and immunological significance (1988) (27)
- CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis (2014) (27)
- An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia (1996) (26)
- Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 ‘START-C’ Phase II Study. (2005) (26)
- Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). (2011) (25)
- Cytoreduction plus low‐dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high‐risk essential thrombocythaemia: an observational study (2013) (25)
- XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia (2010) (25)
- Chronic systemic candidiasis in acute leukemia (1992) (25)
- Cytogenetic studies in blast crisis of Ph-positive chronic granulocytic leukemia: results and prognostic evaluation in 52 patients. (1986) (25)
- Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project (2018) (25)
- Ph-positive chronic myeloid leukemia mimicking essential thrombocythemia and terminating into megakaryoblastic blast crisis: report of two cases with molecular studies. (1993) (25)
- Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response (2016) (25)
- Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia (2018) (25)
- Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 'START-C' Study. (2006) (25)
- Increased CD11b neutrophil expression in Budd–Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera (2004) (25)
- Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study (2011) (24)
- Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib. (2003) (24)
- Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide (2013) (24)
- Low-grade lymphoma: clinical and prognostic studies in a series of 143 patients from a single institution. (1994) (24)
- A Pooled Overall Survival Analysis of The COMFORT Studies: 2 Randomized Phase 3 Trials of Ruxolitinib For The Treatment of Myelofibrosis (2013) (24)
- Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis (2018) (23)
- Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging. (2005) (23)
- Immunophenotypic characteristics of blast crisis of chronic myeloid leukaemia: correlations with clinico-biological features and survival. (1993) (23)
- Non-Hodgkin's lymphoma associated with Gaucher's disease. (1998) (23)
- Usefulness of laparoscopy with liver biopsy in the assessment of liver involvement at diagnosis of Hodgkin's and non-Hodgkin's lymphomas. (1998) (22)
- Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms (2018) (22)
- Predictive factors for anemia response to erythropoiesis‐stimulating agents in myelofibrosis (2017) (21)
- Blast Crisis of Ph-Positive Chronic Myeloid Leukemia with Isochromosome 17q: Report of 12 Cases and Review of the Literature (2000) (21)
- Prognostic factors in chronic myeloid leukaemia. (2009) (21)
- Practical management of patients with chronic myeloid leukemia (2011) (21)
- Central nervous system involvement demonstrated by immunological study in prolymphocytic variant of chronic lymphocytic leukemia. (1989) (20)
- Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C‐MOPP/ABV) as first‐line treatment for patients with advanced hodgkin disease (2000) (20)
- Is the histological classification of chronic granulocytic leukaemia justified from the clinical point of view? (1989) (20)
- Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia (2017) (20)
- Prognostic significance of cytogenetical studies in chronic granulocytic leukaemia. (2009) (20)
- Low-dose vincristine in the treatment of corticosteroid-refractory idiopathic thrombocytopenic purpura (ITP) in non-splenectomized patients. (1980) (19)
- Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. (2014) (19)
- Eosinophilic meningitis in Hodgkin's disease. (1979) (19)
- Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors (2008) (19)
- Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study, (2011) (18)
- Hypercalcemia in a patient with chronic lymphocytic leukemia evolving into Richter's syndrome. (1996) (18)
- Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (2021) (18)
- Large-cell lymphoma: a study of prognostic factors and assessment of five recently proposed predictive systems. (1993) (18)
- Next generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. (2020) (18)
- Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia. (2012) (18)
- Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX). (2017) (17)
- Leukemoid reaction preceding the diagnosis of colorectal carcinoma by four years. (1999) (17)
- Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium (2011) (17)
- Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis (2014) (17)
- Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2) (2013) (17)
- The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) (2013) (17)
- Simultaneous occurrence of multiple myeloma and chronic myeloid leukemia. (2001) (16)
- The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group (2016) (16)
- Prognostication in Primary Myelofibrosis (2012) (16)
- Prognostic evaluation of initial bone marrow histopathological features in chronic granulocytic leukemia. (1989) (16)
- Advances in the understanding and management of primary myelofibrosis (2011) (15)
- Survival in young patients with intermediate‐/high‐risk myelofibrosis: Estimates derived from databases for non transplant patients (2009) (15)
- Refractory anemia with excess of blasts and isochromosome 12p in a patient with primary mediastinal germ-cell tumor. (1994) (15)
- Hepatic granulomas in brucellosis. (1980) (15)
- [Behçet's disease with an onset prior to the appearance of chronic myeloid leukemia]. (1992) (15)
- Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia. (2006) (14)
- Three-year ef fi cacy, safety, and survival fi ndings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelo fi brosis (2013) (14)
- Immune hemolytic anemia and renal failure associated with rifampicin-dependent antibodies with anti-I specificity (1991) (14)
- Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD. (2006) (14)
- Myelofibrosis: an update on current pharmacotherapy and future directions (2013) (14)
- Long-term results of prednisone treatment for the anemia of myelofibrosis (2016) (14)
- Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. (2017) (14)
- Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response (2013) (13)
- The changing profile of Ph-positive chronic myeloid leukemia at presentation: possible impact of earlier diagnosis on survival. (1999) (13)
- Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients (2019) (13)
- Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP). (1986) (13)
- Ruxolitinib and survival improvement in patients with myelofibrosis (2014) (13)
- Iron stores in chronic granulocytic leukaemia at presentation. (2009) (13)
- Trisomy of the long arm of chromosome 1 in patients with hematologic malignancies and solid tumors: report of six cases. (1988) (13)
- Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project (2018) (13)
- Multiple myeloma in primary biliary cirrhosis. (2009) (13)
- [Alpha interferon treatment of idiopathic myelofibrosis]. (1993) (13)
- Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results (2015) (13)
- Idiopathic Myelofibrosis Associated with Ulcerative Colitis (2002) (13)
- Chimeric BCR/ABL gene detected by fluorescence in situ hybridization in three new cases of Philadelphia chromosome-negative chronic myelocytic leukemia. (2003) (13)
- Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon. (2002) (12)
- Risk of relapse and clinico‐pathological features in 103 patients with diffuse large‐cell lymphoma in complete response after first‐line treatment (1998) (12)
- Alleviating anemia and thrombocytopenia in myelofibrosis patients (2016) (12)
- Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000. (2001) (12)
- [Budd-Chiari syndrome associated with chronic myeloproliferative syndromes: analysis of 6 cases]. (1996) (12)
- Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia (2012) (12)
- [Chronic myeloid leukemia after renal transplantation: report of a new case and review of the bibliography]. (1996) (12)
- Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. (2018) (12)
- Acute lymphoid leukemia following polycythemia vera. (1999) (12)
- Acute myeloblastic leukaemia presenting with superior vena cava syndrome due to mediastinal mass. (1984) (11)
- Hypercalcemia as the Presenting Feature of T-Cell Lymphoid Blast Crisis of Ph-Positive Chronic Myeloid Leukemia (2001) (11)
- Magnetic resonance imaging in myelofibrosis and essential thrombocythaemia: contribution to differential diagnosis (1999) (11)
- [Idiopathic myelofibrosis: initial features, evolutive patterns and survival in a series of 106 patients]. (1997) (11)
- Idiopathic Myelofibrosis Associated with Classic Polyarteritis Nodosa (2003) (11)
- Comparison of the Efficacy of Placebo and Best Available Therapy for the Treatment of Myelofibrosis in the COMFORT Studies (2011) (11)
- Idiopathic Myelofibrosis Associated with Primary Biliary Cirrhosis (2002) (11)
- Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes (2018) (10)
- Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. (2012) (10)
- JAK inhibitors: beyond spleen and symptoms? (2013) (10)
- Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection (2017) (10)
- Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model: Prognostication in myelofibrosis. (2020) (10)
- A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF) (2016) (10)
- A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: a Study of the International Working Group for Myeloproliferative Neoplasm Research and Treatment (IWG-MRT). (2009) (9)
- Multiple myeloma following essential thrombocythemia. (1995) (9)
- Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis (2014) (9)
- [Chylothorax as the initial manifestation of Waldenström's macroglobulinemia]. (1987) (9)
- Myelofibrosis: biology and treatment options (2007) (9)
- Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study (2008) (9)
- Successful autografting in chronic myelogenous leukaemia using Philadelphia negative blood progenitor cells mobilized with rHuG‐CSF alone in a patient responding to alpha‐interferon (1997) (9)
- Evaluation of resistance to HIV‐1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors (2018) (9)
- Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF). (2017) (9)
- Chronic neutrophilic leukemia with dysplastic features. (1990) (8)
- Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. Italian Cooperative CML Study Group. (1994) (8)
- Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up (2013) (8)
- Novel therapies for myelofibrosis (2015) (8)
- [Tuberculosis in chronic myeloproliferative syndromes: its incidence and principle characteristics in a series of 562 patients]. (1991) (8)
- Single-agent therapy with oral mercaptopurine for nonlymphoid blast crisis of chronic myeloid leukemia (2001) (8)
- Association of cytokine levels and reductions in spleen size in COMFORT-II, a phase III study comparing ruxolitinib to best available therapy (BAT). (2012) (8)
- Conventional and molecular cytogenetic studies to characterize 32 complex variant Philadelphia translocations in patients with chronic myeloid leukemia. (2019) (8)
- [Polyarthritis, cutaneous vasculitis and migrant thrombophlebitis of possible immune origin associated with chronic myelomonocytic leukemia]. (1987) (8)
- Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis (2022) (8)
- Treatment of blast crisis of chronic myelogenous leukemia with vincristine, prednisone, and cytarabine. (1985) (8)
- Transient pancytopenia after non-A non-B non-C acute hepatitis preceding acute lymphoblastic leukemia. (1998) (8)
- Tumour lysis syndrome with hypocälcaemia in accelerated chronic granulocytic leukaemia. (1982) (8)
- The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs), (2011) (8)
- Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis (2020) (8)
- Early T-cell features in blast crisis of Ph1-positive chronic myeloid leukaemia. (2009) (8)
- Prognostic risk models for transplant decision-making in myelofibrosis (2018) (8)
- Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial (2015) (8)
- Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG) (2013) (8)
- Chronic neutrophilic leukemia with marked myelodysplasia terminating in blast crisis (1988) (7)
- Conventional therapeutic options have limited impact on MPN symptoms: Insights from a prospective analysis of the MPN-SAF TSS (2012) (7)
- BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia. (2015) (7)
- Detection of inflammatory monocytes but not mesenchymal stem/stromal cells in peripheral blood of patients with myelofibrosis (2018) (7)
- Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naïve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib (2019) (7)
- Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea (2020) (7)
- Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. (2019) (7)
- Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis (2011) (7)
- Porphyria cutanea tarda and chronic myelomonocytic leukemia (1989) (7)
- Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain (2014) (7)
- Non‐hodgkin's lymphoma of unfavourable histology: A multivariate analysis of factors predicting the response to chop (1987) (7)
- Non-Hodgkin's Lymphoma Following Untreated Essential Thrombocythemia (2000) (6)
- Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. (2020) (6)
- Polycythaemia vera following non-Hodgkin's lymphoma. (1992) (6)
- Acute transformation of chronic myelomonocytic leukaemia: a multivariate study of predictive factors (1989) (6)
- Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG) (2013) (6)
- Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients. (2007) (6)
- Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy (2011) (6)
- Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group (2019) (6)
- P53 Tumor suppressor gene in chronic myelogenous leukemia: A sequential study (1995) (6)
- RBC-transfusion guidelines update. (2012) (6)
- The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients (2012) (6)
- Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide (2020) (6)
- Momelotinib reduces transfusion requirements in patients with myelofibrosis (2022) (5)
- Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group (2016) (5)
- Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results (2012) (5)
- Imatinib mesylate (STI571) treatment in patients with chronic‐phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation (2003) (5)
- A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP). (2006) (5)
- Clinical Evolution to Primary Myelofibrosis - Blast Phase: An International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Collaborative Retrospective Analysis. (2007) (5)
- Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms (2017) (4)
- Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT). (2012) (4)
- Scleroderma Associated with Idiopathic Myelofibrosis. (1990) (4)
- Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib. (2021) (4)
- Sibling versus Unrelated Donor Allogeneic Hematopoietic Cell Transplantation for CML: Refined HLA-matching shows more GVHD but not less relapse Blood Marrow (2010) (4)
- Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation. (2011) (4)
- Decreased bone marrow iron in chronic granulocytic leukaemia: A consistent finding not reflecting iron deficiency (1986) (4)
- [Hemopoietic progenitor cell transplantation: 20 years' experience at the Hematology School "Farreras-Valentí"/Clinical Hospital of Barcelona]. (1997) (4)
- Pure red cell aplasia associated with chronic myelomonocytic leukaemia. (1989) (4)
- Molecular monitoring of complete cytogenetic responders following treatment with imatinib (STI571, Gleevec) for CML: A report from the UKSTI571 study group. (2002) (4)
- Survival and Prognosis in Patients with First-Line Imatinib Treatment Under Particular Consideration of Death Due to Chronic Myeloid Leukemia (2014) (4)
- Chronic granulocytic leukaemia in asplenic patients (1990) (4)
- Myeloproliferative disease in two young siblings (1984) (4)
- Thrombocytosis in quiescent chronic granulocytic leukaemia after vincristine and 6-mercaptopurine therapy. (1980) (4)
- Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis (2013) (4)
- The ERCC2 Gln/Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis (2013) (4)
- Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL) (2015) (4)
- Gender Differences and MPN Symptom Burden : An Analysis by the MPN Quality of Life International Study Group (MPN-QOL ISG) (2014) (3)
- Sequential study of myeloid differentiation antigens of neutrophil granulocytes in different phases of chronic myeloid leukaemia: natural history and prognostic significance. (1993) (3)
- [Changes in the ratio of coagulation factors as the only manifestation of hepatic toxicity caused by 6-mercaptopurine]. (1985) (3)
- The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia (2015) (3)
- Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis. (2020) (3)
- [Sepsis by Candida tropicalis in patients with granulocytopenia. A study of 10 cases]. (1994) (3)
- Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use : a Retrospective Evaluation of 1334 Patients (2014) (3)
- [Philadelphia chromosome-positive chronic myeloid leukemia in the elderly: presenting features, natural history and survival]. (1999) (3)
- Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study) (2014) (3)
- [Adriamycin and pregnancy]. (1980) (3)
- CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry (2013) (3)
- Symptom Burden and Health-Related Quality Of Life (HRQoL) In Patients With Myelofibrosis (MF) Treated With Fedratinib (SAR302503) In a Phase III Study (JAKARTA) (2013) (3)
- Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib : ENESTcmr 12-month (mo) follow-up (2012) (3)
- [Erythroblastopenia associated with chronic myelomonocytic leukemia]. (1989) (3)
- PS1465 SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB <10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL (2019) (3)
- Prognosis of chronic myeloid leukemia: studies from the Barcelona Group. (1993) (3)
- A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2) (2021) (3)
- DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status (2010) (3)
- [Causes of death in chronic myeloid leukemia. Analysis of 109 patients]. (1991) (3)
- JAKARTA: A phase III, multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF with splenomegaly. (2012) (3)
- Interferon alpha-2b for Essential Thrombocythaemia: Results in 13 Previously Untreated Patients. (1991) (3)
- Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms (2013) (3)
- Polyethylene glycol interferon-alpha2b alone or in combination with low-dose Ara-C in patients newly diagnosed with chronic myeloid leukemia. (2004) (3)
- Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon. (2001) (3)
- Sequential appearance of immunoblastic lymphoma and acute nonlymphocytic leukemia in a patient with angioimmunoblastic lymphadenopathy. (1985) (3)
- Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients (2022) (2)
- The EHA Research Roadmap: Malignant Myeloid Diseases (2021) (2)
- Late response to donor lymphocyte infusions in patients with chronic myeloid leukemia relapsing after allogeneic stem cell transplantation. (2002) (2)
- [T lymphoblastic leukemia with leukemoid reaction or the extramedullary blast crisis of Philadelphia chromosome-negative chronic myeloid leukemia? Comments apropos 2 cases]. (1990) (2)
- Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis (2012) (2)
- A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr-Mutated Low Risk Essential Thrombocythemia (2015) (2)
- MPN-356: Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib (2021) (2)
- [Blast crisis of chronic myeloid leukemia with positive Philadelphia chromosome: course and clinico-hematologic profile in 80 patients]. (1990) (2)
- Excess Mortality in Polycythemia Vera and Essential Thrombocythemia (2018) (2)
- [Initial iron deposits in idiopathic myelofibrosis. Analysis of 20 patients]. (1993) (2)
- PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT (2019) (2)
- [Hodgkin's disease with cutaneous fistulization of the adenopathies]. (1985) (2)
- [Laparoscopic splenectomy as an alternative to open surgery in the treatment of autoimmune thrombocytopenia]. (1998) (2)
- Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials (2016) (2)
- Iron stores in essential thrombocythaemia. A study of 26 patients. (1989) (2)
- Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients (2014) (2)
- PRIMARY MYELOFIBROSIS, POST-ET AND POST-PV MYELOFIBROSIS HAVE DISTINCT CLINICAL PROFILES AND SYMPTOMATIC BURDENS : AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG) (2015) (2)
- Advanced lymphoma and CHOP chemotherapy. (1986) (2)
- Clinical Validation of the Myelofibrosis Transplant Scoring System in an Independent Series of Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Transplantation (2019) (2)
- Chronic Myelogenous Leukemia Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with α-interferon (2002) (2)
- Associations between gender , disease features and symptom burden in the MPN population : An analysis by the MPN QOL International Working Group (2016) (2)
- PHM12 COST-EFFECTIVENESS OF DASATINIBVS IMATINIB 800 MG/ DAY IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN SPAIN (2007) (2)
- Reply to ‘Re: Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Alvarez-Larrán A et al.’ by Westerman et al. (2008) (2)
- [Treatment of essential thrombocythemia]. (2013) (2)
- PF415 EFFICACY AND SAFETY FOLLOWING DOSE REDUCTION OF BOSUTINIB IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA: ANALYSIS OF THE PHASE 4 BYOND TRIAL (2019) (2)
- [Alpha interferon treatment in idiopathic hypereosinophilic syndrome resistant to conventional therapy]. (1996) (2)
- T-cell lymphoblastic lymphoma with blood eosinophilia and associated myeloid malignancy. (1993) (2)
- [Idiopathic myelofibrosis: clinical course, survival, and causes of death in a series of 60 patients]. (1990) (2)
- Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs) (2015) (2)
- Prognostic Factors in Classic Myeloproliferative Neoplasms (2011) (1)
- Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs (2015) (1)
- Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia (2013) (1)
- [Coombs-positive autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia]. (1987) (1)
- [Treatment of Hodgkin's disease with ABVD]. (1984) (1)
- [Primary myelofibrosis: description of a series of 53 patients]. (1989) (1)
- Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects (2014) (1)
- [Cytolytic activity by lymphokines (LAK activity) in chronic myeloid leukemia]. (1995) (1)
- Longitudinal study of serum ferritin concentrations in chronic granulocytic leukaemia. (1988) (1)
- EUROPEAN SUB-REGISTRY OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS (PTS) IN FAILURE AFTER IMATINIB THERAPY (IFP): RATIONALE, STUDY DESIGN AND CURRENT STATUS. A STUDY FROM THE EUROPEAN LEUKEMIANET (ELN) (2010) (1)
- Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (2021) (1)
- [Acute myeloproliferative syndrome after alkylating agent treatment in a case of multiple myeloma]. (1982) (1)
- Pomalidomide Therapy in Myelofibrosis: 2-Year Follow-up of a Randomized Phase 2 Study. (2009) (1)
- Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr. (2014) (1)
- [Occult involvement of bone marrow in Hodgkin's disease: detection with magnetic resonance]. (1996) (1)
- Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient reported outcomes (PROs) in the phase III PERSIST-1 trial. (2016) (1)
- [Osteolytic lesions in idiopathic myelofibrosis: presentation of 2 cases]. (1983) (1)
- Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis (2020) (1)
- [Multiple myeloma: description of a series of 170 cases]. (1984) (1)
- Reply to Westerman et al.: ‘Re: Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Alvarez-Larrán A et al. Leukemia 2007; 21: 1218–1223’ (2008) (1)
- [Autoimmune hemolytic anemia after 9 years of treatment with alpha-methyldopa]. (1993) (1)
- [Primary MALT-type lymphoma of the breast]. (1998) (1)
- Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects (2013) (1)
- [Treatment with m-AMSA in the blast crisis of chronic myeloid leukemia]. (1988) (1)
- and Treatment study of the International Working Group for Myelofibrosis Research New prognostic scoring system for primary myelofibrosis based on a (2013) (1)
- Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms (2017) (1)
- Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group. (2009) (1)
- Impact Of Splenomegaly On Mpn Symptoms And Association With Clinical Features : An Analysis By The Mpn Quality Of Life International Study Group (2016) (1)
- Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients (2014) (1)
- P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS (2022) (1)
- thrombocythemia and polycythemia vera transformation and new nonmyeloid malignancies in essential gene predisposes to leukemic XPD A polymorphism in the (2013) (1)
- [Essential thrombocythemia developing into acute leukemia]. (1983) (1)
- Iron stores in essential thrombocythaemia (1989) (1)
- [Thrombosis of the portal vein as a complication of paroxysmal nocturnal hemoglobinuria]. (1990) (1)
- [Chronic myelomonocytic leukemia and solid neoplasms: is it a causal or a fortuitous association?]. (1989) (1)
- Prediction of Overall Survival in 520 Patients with Primary Myelofibrosis: Outcome Update of the Dynamic International Prognostic Scoring System (DIPSS) Patient Cohort (2012) (1)
- [Granulocyte abnormal chromatin clumping syndrome: report of a new case and review of the literature]. (1995) (1)
- Palpitations And Arrhythmia In 3649 High-Risk Patients With Essential Thrombocythemia : Results From The Prospective Long-Term Observational Exels Study (2016) (1)
- Leukemianet Recommendations from an expert panel on behalf of the European Evolving concepts in the management of chronic myeloid leukemia. (2011) (1)
- [Bone marrow transplantation from unrelated donors in chronic myeloid leukemia: the results in 15 patients]. (1995) (1)
- [Multiple myeloma after monoclonal gammopathy of uncertain significance. Study of 10 patients]. (1993) (1)
- Safety and Efficacy of Nilotinib Dose Escalation 600mg BID in Patients (pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). (2007) (1)
- Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib. (2021) (1)
- [Coombs-positive autoimmune hemolytic anemia as a striking initial manifestation of myelodysplastic syndromes]. (1990) (1)
- Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients (2018) (1)
- A Ruxolitinib Individual Supply Program for Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (2011) (1)
- An International Multicenter Project on Secondary Myelofibrosis (2016) (0)
- [Analysis of response to treatment. Considerations on changing prognostic variables (time-dependent)]. (1989) (0)
- Impact Of Ruxolitinib On The Natural History Of Patients With Primary Myelofibrosis: A Retrospective Comparison Of The DIPSS and The Comfort-2 Cohorts (2013) (0)
- [Essential thromboembolism: study of 9 cases]. (1985) (0)
- Platelet Antiaggregant Therapy Prevents Venous Thrombosis in Patients with JAK2 V617F Positive Essential Thrombocythemia without Indication of Cytoreductive Treatment. (2009) (0)
- Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project (2018) (0)
- INACTIVATING MUTATIONS OF THE HISTONE METHYLTRANSFERASE EZH2 ARE ASSOCIATED WITH CHROMOSOME 7 ABNORMALITIES IN MYELOID DISORDERS (2010) (0)
- [Neoplasms associated with chronic myeloid leukemia. Incidence in a series of 288 patients]. (1988) (0)
- [Molecular analysis of chronic Philadelphia chromosome negative myeloid leukemia: study of 6 cases]. (1992) (0)
- [Allogeneic marrow transplantation in severe bone marrow aplasia. Factors determining the outcome in a series of 27 consecutive cases]. (1985) (0)
- [Chronic myelogenous leukaemia. Report of a series of 207 patients]. (1983) (0)
- [Cytogenetic and therapeutic results of a protocol including splenectomy and intensive polychemotherapy in Ph'-positive chronic myeloid leukemia]. (1986) (0)
- complete cytogenetic remission on imatinib Molecular monitoring in chronic myeloid leukemia patients who achieve (2013) (0)
- Assessment of iron stores in hospitalized patients. (1991) (0)
- Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with JAK2 and TET2 Mutational Status. (2009) (0)
- [Treatment with cyclosporin A of the anemia associated with chronic lymphatic leukemia]. (1990) (0)
- [Chronic myeloid leukemia: comparison of monotherapy with busulfan with busulfan and vincristine and 6-mercaptopurine cycles]. (1986) (0)
- [Bone marrow transplantation in acute leukaemia (author's transl)]. (1981) (0)
- Gene Expression Profiling Distinguishes Essential Thrombocythemia from Polycythemia Vera Patients and Identifies a Common Expressed Set of Genes in Relation to JAK2V 617F Status (2008) (0)
- [Macrocytic anemia due to folic acid deficiency and non-Hodgkin's lymphoma associated with prolonged diphenylhydantoin ingestion]. (1985) (0)
- myelofibrosis in primary MPL , or CALR , JAK2 Clinical effect of driver mutations of (2014) (0)
- myelofibrosis phase 3 study comparing ruxolitinib with best available therapy for Three-year efficacy, safety, and survival findings from COMFORT-II, a (2013) (0)
- international expert panel and primary myelofibrosis: recommendations from an ad hoc diagnostic criteria for polycythemia vera, essential thrombocythemia, Proposals and rationale for revision of the World Health Organization (2009) (0)
- Pulmonary embolism secondary to heart infiltration as a complication of chronic myelomonocytic leukaemia in transformation. (1989) (0)
- mutational status predicts poor survival in myelofibrosis EZH2 (2012) (0)
- Benign hematopoietic progenitors in chronic myeloid leukemia: Current status and future prospects (1994) (0)
- Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients (2012) (0)
- Association Between EZH2 and Other Acquired Mutations In Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasms (2010) (0)
- Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up. (2013) (0)
- Effect of tyrosine kinase inhibitors on the cytotoxic activity against HIV-1 infection (2017) (0)
- [Neuropathy of the brachial plexus in a patient with acute promyelocytic leukemia]. (1988) (0)
- [Treatment with CEP (CCNU, VP-16 and prednimustine) in Hodgkin's disease resistant to CVPP and ABVD. Results in 21 patients]. (1988) (0)
- Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis (2022) (0)
- Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome (2019) (0)
- A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Short title: Prognostic scoring system of primary myelofibrosis (2008) (0)
- A study of the myeloid differentiation antigens of the peripheral blood neutrophil granulocytes in the different evolutive phases of chronic myeloid leukemia (1991) (0)
- chronic-phase chronic myeloid leukemia after failure of imatinib therapy Dasatinib induces notable hematologic and cytogenetic responses in (2013) (0)
- [Prognostic studies and current trends in the treatment of chronic myeloid leukemia]. (1983) (0)
- Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2) (2018) (0)
- WHERE SCIENCE MEETS CLINICAL PRACTICE (2014) (0)
- The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-α a Background and Objectives (2004) (0)
- Efficacy and tolerability of danazol as a treatment for the (2005) (0)
- The European Leukemia Net CML Registry - Objectives, Achievements and First Results. (2006) (0)
- P1026: COMPARATIVE GENOMIC PROFILING OF MYELOPROLIFERATIVE NEOPLASMS PRESENTING WITH AND WITHOUT SPLANCHNIC VEIN THROMBOSIS (2022) (0)
- Overall Survival and Prognosis in 2190 Patients with First-Line Imatinib Treatment Considering Death Due to Chronic Myeloid Leukaemia as the Only Event (2014) (0)
- [Serum muramidase activity in chronic myeloid leukemia]. (1984) (0)
- Cep ccnu vp 16 and prednimustine therapy for hodgkin's disease resistant to cvpp and abvd results of 21 patients (1988) (0)
- Clinical Phenotype and Genotype Correlations with Time to Progression into Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis (2017) (0)
- [Blast crisis mimicking acute leukaemia as first manifestations of chronic myelogenous leukaemia. Report of three cases (author's transl)]. (1981) (0)
- Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression (2014) (0)
- Myeloproliferative Neoplasms Research and Treatment ) formyelofibrosis : a study by the IWG-MRT ( International Working Group A dynamic prognostic model to predict survival in primary (2010) (0)
- Response: Capturing variables with prognostic relevance in development of a new scoring system for primary myelofibrosis (2010) (0)
- [Syndrome of aplastic anemia-paroxysmal nocturnal hemoglobinuria. Comparative study of the clinical and biological features with the disease paroxysmal nocturnal hemoglobinuria]. (1980) (0)
- Acute Leukemias Interferon α plus intermittent oral AraC ocfosfate ( YNK-01 ) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon (2001) (0)
- Tissue Factor and Soluble Markers of Platelet and Endothelial Activation in Essential Thrombocythemia: Relationship with Thrombosis and JAK2 V617F Mutation Status. (2006) (0)
- Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations (2018) (0)
- [Long-term survival in chronic myeloid leukemia: frequency and fundamental characteristics in a series of 100 patients]. (1993) (0)
- chronic myeloid leukemia: 2013 European LeukemiaNet recommendations for the management of (2013) (0)
- Contents, Vol. 85, 1991 (1991) (0)
- What we can do about anemia in myelofibrosis (2015) (0)
- [Chronic myeloid leukosis. Current status]. (1991) (0)
- [Adult acute lymphoblastic leukemia: preliminary results of the LAL-86 protocol]. (1990) (0)
- Accurately assessing risk in your myeloproliferative neoplasm patient (2016) (0)
- The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study. (2016) (0)
- Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry (2011) (0)
- [Splenomegalic pancytopenia of probable immune origin: cure after treatment with glucocorticoids]. (1996) (0)
- [Monoclonal origin of chronic myeloproliferative syndromes]. (1983) (0)
- Natural history of polycytemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis (2020) (0)
- [Gastric adenocarcinoma associated with Hodgkin's disease with infiltration of the tonsils and gastric serous membrane]. (1984) (0)
- [Clinico-biological expression of chronic granulocytic leukemia in the diagnostic phase and its prognostic significance]. (1984) (0)
- [Allogenic bone-marrow transplantation in severe marrow aplasia. Analysis of 12 consecutive cases (author's transl)]. (1981) (0)
- [Mediastinal tumor in a patient with acute myeloblastic leukosis]. (1984) (0)
- Conventional and New Treatment Modalities in Myelofibrosis and the Current Role of Transplantation (2008) (0)
- [Paroxysmal nocturnal haemoglobinuria. Report of twenty-one cases and a review of the literature (author's transl)]. (1979) (0)
- Increased Platelet Turnover and Platelet P-Selectin in Patients with Essential Thrombocythemia and Thrombosis. (2004) (0)
- European Sub-Registry of Chronic Myelogenous Leukemia (CML) Patients (pts) in Failure after Imatinib Therapy (IFP): Rationale, Study Design and Current Enrollment. (2006) (0)
- [Chronic myeloid leukemia 2008]. (2008) (0)
- myelogenous leukemia progenitors in long-term culture Autologous activated natural killer cells suppress primitive chronic (2002) (0)
- Overall survival and prognosis in patients with chronic myeloid leukaemia allocated to first-line imatinib treatment - new results from the EUTOS "In-Study" registry (2013) (0)
- MPN-147: Dynamic and Time-To-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naïve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib (2020) (0)
- [Erythrocyte acetylcholinesterase activity in paroxysmal nocturnal haemoglobinuria. Its relationship with the clinical-biological expression of the disease (author's transl)]. (1979) (0)
- for myelofibrosis research and treatment (IWG-MRT) response in myelofibrosis with myeloid metaplasia: On behalf of the IWG International Working Group (IWG) consensus criteria for treatment (2013) (0)
- Increased Granulocyte CD11b and Monocyte Tissues Factor Expression in Patients with Essential Thrombocythemia and Thrombosis. (2004) (0)
- Subject Index, Vol. 85, 1991 (1991) (0)
- BAALC -Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia (2013) (0)
- [Ferrokinetic studies in the initial evaluation of idiopathic myelofibrosis: results in 18 patients]. (1992) (0)
- P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT (2022) (0)
- Comparison of the Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients. (2012) (0)
- [Chronic myeloid leukemia: a decade of progress]. (1990) (0)
- [Liver changes in bone marrow transplantation]. (1991) (0)
- [Chronic myeloid leukemia beginning as thrombocythemia. Analysis of 5 cases]. (1992) (0)
- GENETIC VARIATION AT HBS1L-MYB AND GFI1B-GTF3C5 INFLUENCES WHETHER JAK2 V617F MUTATED MPN PRESENT WITH ET OR PV (2016) (0)
- [Treatment of various lymphoproliferative syndromes with deoxycoformycin: results in 6 patients]. (1990) (0)
- Overall Survival and Prognosis In Patients With First-Line Imatinib Treatment Under Consideration Of Death Due To Any Cause and Death Due To Chronic Myeloid Leukemia Only (2013) (0)
- Tips improves survival in Budd-Chiari Syndrome (BCS) (2000) (0)
- [Molecular biology studies in chronic myeloid leukemia]. (1993) (0)
- Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients (2018) (0)
- [Association of cutaneous mastocytosis with acute leukemia and adenocarcinoma]. (1985) (0)
- Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms (2018) (0)
- [Does Ph1-negative chronic myeloid leukemia exist?]. (1986) (0)
- Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients (2018) (0)
- Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT) (2015) (0)
- FRI-434-Role of next generation sequencing in the etiological diagnosis of splanchnic venous thrombosis (2019) (0)
- [Granulocyte alkaline phosphatase activity in the chronic phase and blastic crisis of chronic myeloid leukemia. Sequential study of 43 patients]. (1992) (0)
- Development of an MF patient reported outcome (PRO) tool for FDA qualification: Comprehensive literature search and physician cognitive debriefing results (2016) (0)
- Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group (2016) (0)
- Reply to: Correspondence on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis". (2020) (0)
- expert panel primary myelofibrosis: recommendations from an ad hoc international diagnostic criteria for polycythemia vera, essential thrombocythemia, and Proposals and rationale for revision of the World Health Organization (2013) (0)
- Essential Thrombocythemia in Young Individuals: Frequency and Risk Factors for Vascular Events and Evolution to Myelofibrosis in 126 Patients. (2006) (0)
- BAALC-associated miR-3151 is an Independent Prognostic Factor in Young Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia (2013) (0)
- Patient’s Information and Examinations Needed Before Planning Therapy in the Myeloproliferative Neoplasms (2012) (0)
- [Neoplasms associated with chronic lymphatic leukemia. Incidence and characteristics in a series of 232 patients]. (1989) (0)
- Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy (2015) (0)
- Cytoreduction Plus Low-Dose Aspirin Versus Cytoreduction in Monotherapy As Primary Prophylaxis of Thrombosis in Patients with Essential Thrombocythemia. (2012) (0)
- [T lymphoid blast crisis of Philadelphia chromosome-positive chronic myeloid leukemia: analysis of 3 cases]. (1991) (0)
- Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly (2021) (0)
- [Chronic myeloid leukemia after chemotherapy treatment for non-Hodgkin's lymphoma]. (1992) (0)
- JAK2 Mutations at Exon 12 and 14 in Polycythemia Vera and Idiopathic Erythrocytosis: Incidence and Correlation with Clinical Characteristics. (2007) (0)
- Imatinib Dose Reduction in Patients with Chronic Myeloid Leukemia in Sustained Deep Molecular Response: CML‐259 (2018) (0)
- [Chronic myelomonocytic leukemia. Analysis of 21 cases]. (1985) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Francisco Cervantes?
Francisco Cervantes is affiliated with the following schools:
